对照组的患者接受常规GP化疗方案，实验组的患者接受在常规GP化疗方案基

对照组的患者接受常规GP化疗方案，实验组的患者接受在常规GP化疗方案基础上联合使用信迪利单抗注射液静点。两组患者治疗前后血清肿瘤标记物CYFRA211、CEA、CA125以及两组患者T淋巴细胞亚群CD3+、CD4+、CD8+、CD4+/CD8+变化水平被对比分析。同时，对比分析两组患者6个月时的临床疗效。结果：两组患者治疗后血清肿瘤标记物CYFRA211、CEA、CA125均较治疗前降低，差异有统计学意义（p=0.00）。具体而，实验组较对照组降低更加明显，差异有统计学意义（CYFRA211、CA125，p=0.00；CEA，p=0.01；CD3+、CD4+水平实验组治疗后较对照组高，具有统计学意义（CD3+，p=0.00；CD4+，p=0.01）。CD8+变化无显著性（p=0.14）；CD4+/CD8+水平实验组高于对照组，差异具有显著性（p=0.02）。实验组完全缓解率（CR）为22%，对照组为8%，具有统计学差异（p=0.04）。进展率（PD）实验组明显低于对照组，具有统计学意义（p=0.02），总有效率（RR）实验组较对照组更有优势，差异具有统计学意义（p=0.01）。结论：信迪利单抗联合化疗治疗晚期非小细胞肺癌与单纯化疗相比具有明显的治疗效果，能够显著降低血清肿瘤标记物水平，改善患者细胞免疫功能，增加治疗总有效率，降低患者进展的风险。。关键词：信迪利单抗，化疗，非小细胞肺癌，肿瘤标记物，免疫功能引言：

0/5000

源语言: -

目标语言: -

结果 (英语) 1: [复制]

复制成功！

Patients in the control group received conventional GP chemotherapy, and patients in the experimental group received intravenous injection of Sintilimab in combination with conventional GP chemotherapy. The serum tumor markers CYFRA211, CEA, CA125 before and after treatment in the two groups of patients and the changes in T lymphocyte subsets CD3+, CD4+, CD8+, CD4+/CD8+ in the two groups were compared and analyzed. At the same time, the clinical efficacy of the two groups of patients at 6 months was compared and analyzed. Results: The serum tumor markers CYFRA211, CEA, and CA125 after treatment in the two groups were all lower than before treatment, and the difference was statistically significant (p=0.00). Specifically, the experimental group decreased more significantly than the control group, and the difference was statistically significant (CYFRA211, CA125, p=0.00; CEA, p=0.01; CD3+ and CD4+ levels in the experimental group were higher than the control group after treatment, which was statistically significant ( CD3+, p=0.00; CD4+, p=0.01). There was no significant change in CD8+ (p=0.14); the level of CD4+/CD8+ in the experimental group was higher than that in the control group, and the difference was significant (p=0.02). Complete remission rate in the experimental group (CR) is 22%, the control group is 8%, there is a statistical difference (p=0.04). The progress rate (PD) of the experimental group is significantly lower than the control group, with statistical significance (p=0.02), the total effective rate ( RR) The experimental group has more advantages than the control group, and the difference is statistically significant (p=0.01). Conclusion: Sintilimab combined with chemotherapy in the treatment of advanced non-small cell lung cancer has a significant therapeutic effect compared with chemotherapy alone. Reduce the level of serum tumor markers, improve the patient's cellular immune function, increase the total effective rate of treatment, and reduce the risk of patient progression... Keywords: Sintilimab, chemotherapy, non-small cell lung cancer, tumor markers, immune function Introduction:

正在翻译中..

结果 (英语) 2:[复制]

复制成功！

Patients in the control group received a routine GP chemotherapy program, and patients in the experimental group received a combination of synthesizer static points based on the conventional GP chemotherapy program. The change levels of Serum tumor markers CYFRA211, CEA, CA125 and T lymphocyte subgroup CD3, CD4, CD8, CD4,/CD8 plus were compared and analyzed in two groups of patients. At the same time, the clinical efficacy of 6 months was compared and analyzed in two groups of patients. RESULTS: The serum tumor markers CYFRA211, CEA and CA125 were lower than before treatment in two groups of patients, and the difference was statistically significant (p-0.00). Specifically, the experimental group decreased more significantly than the control group, and the differences were statistically significant (CYFRA211, CA125, p-0.00; CEA, p-0.01; CD3-plus, CD4-level experimental group was higher than the control group, with statistical significance (CD3,p=0.00; CD4?, p=0.01). There was no significance in the change of CD8 plus (p-0.14), and the horizontal experimental group of CD4-/CD8-plus was higher than that of the control group, and the difference was significant (p-0.02). The total remission rate (CR) was 22% in the experimental group and 8% in the control group, with statistical differences (p-0.04). The progress rate (PD) experimental group was significantly lower than the control group, which had statistical significance (p-0.02), and the total efficiency (RR) experimental group had more advantages than the control group, and the difference was statistically significant (p-0.01). Conclusion: The treatment of advanced non-small cell lung cancer with single-cell chemotherapy has obvious therapeutic effect, which can significantly reduce the level of serum tumor markers, improve the patient's cellular immune function, increase the total efficiency of treatment and reduce the risk of patient progression. Keywords: Cyndili monoanti, chemotherapy, non-small cell lung cancer, tumor markers, immune function. Introduction:

正在翻译中..

结果 (英语) 3:[复制]

复制成功！

Patients in the control group received conventional GP chemotherapy, while patients in the experimental group received intravenous injection of sindilimab on the basis of conventional GP chemotherapy. The changes of serum tumor markers cyfra211, CEA, CA125 and T lymphocyte subsets CD3 +, CD4 +, CD8 +, CD4 + / CD8 + in the two groups before and after treatment were compared and analyzed. At the same time, the clinical efficacy of the two groups at 6 months was compared and analyzed. Results: the serum tumor markers cyfra211, CEA and CA125 in the two groups after treatment were significantly lower than those before treatment (P = 0.00). Specifically, the experimental group was more significantly lower than the control group, the difference was statistically significant (cyfra211, CA125, P = 0.00; CEA, P = 0.01; CD3 +, CD4 + levels after treatment in the experimental group were higher than those in the control group, with statistical significance (CD3 +, P = 0.00; CD4 +, P = 0.01). The level of CD4 + / CD8 + in the experimental group was higher than that in the control group (P = 0.02). The complete remission rate (CR) was 22% in the experimental group and 8% in the control group (P = 0.04). The progression rate (PD) of the experimental group was significantly lower than that of the control group (P = 0.02). The total effective rate (RR) of the experimental group was better than that of the control group (P = 0.01). Conclusion: cindilimab combined with chemotherapy in the treatment of advanced non-small cell lung cancer has obvious therapeutic effect, can significantly reduce the level of serum tumor markers, improve the patient's cellular immune function, increase the total effective rate of treatment, and reduce the risk of progression of patients.. Key words: cindilimab, chemotherapy, non-small cell lung cancer, tumor markers, immune function introduction:

正在翻译中..

其它语言

本翻译工具支持: 世界语, 丹麦语, 乌克兰语, 乌兹别克语, 乌尔都语, 亚美尼亚语, 伊博语, 俄语, 保加利亚语, 信德语, 修纳语, 僧伽罗语, 克林贡语, 克罗地亚语, 冰岛语, 加利西亚语, 加泰罗尼亚语, 匈牙利语, 南非祖鲁语, 南非科萨语, 卡纳达语, 卢旺达语, 卢森堡语, 印地语, 印尼巽他语, 印尼爪哇语, 印尼语, 古吉拉特语, 吉尔吉斯语, 哈萨克语, 土库曼语, 土耳其语, 塔吉克语, 塞尔维亚语, 塞索托语, 夏威夷语, 奥利亚语, 威尔士语, 孟加拉语, 宿务语, 尼泊尔语, 巴斯克语, 布尔语(南非荷兰语), 希伯来语, 希腊语, 库尔德语, 弗里西语, 德语, 意大利语, 意第绪语, 拉丁语, 拉脱维亚语, 挪威语, 捷克语, 斯洛伐克语, 斯洛文尼亚语, 斯瓦希里语, 旁遮普语, 日语, 普什图语, 格鲁吉亚语, 毛利语, 法语, 波兰语, 波斯尼亚语, 波斯语, 泰卢固语, 泰米尔语, 泰语, 海地克里奥尔语, 爱尔兰语, 爱沙尼亚语, 瑞典语, 白俄罗斯语, 科西嘉语, 立陶宛语, 简体中文, 索马里语, 繁体中文, 约鲁巴语, 维吾尔语, 缅甸语, 罗马尼亚语, 老挝语, 自动识别, 芬兰语, 苏格兰盖尔语, 苗语, 英语, 荷兰语, 菲律宾语, 萨摩亚语, 葡萄牙语, 蒙古语, 西班牙语, 豪萨语, 越南语, 阿塞拜疆语, 阿姆哈拉语, 阿尔巴尼亚语, 阿拉伯语, 鞑靼语, 韩语, 马其顿语, 马尔加什语, 马拉地语, 马拉雅拉姆语, 马来语, 马耳他语, 高棉语, 齐切瓦语, 等语言的翻译.